22.03.2010 10:00:00

AngioDynamics Welcomes Recently Published Book on Irreversible Electroporation and Patient Experiences

AngioDynamics (NASDAQ:ANGO) today welcomed the publication of the book "Irreversible Electroporation,” published by Springer Berlin Heidelberg.

The book is edited by Boris Rubinsky, a Professor of the Graduate School at the University of California, Berkeley.

The book’s chapters include one by the book’s editor and Dr. Gary Onik of the School of Medicine at the University of Central Florida, titled, ‘Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer,’ and another by Dr. Kenneth Thomson of The Alfred hospital in Melbourne Australia titled, ‘Human Experience with Irreversible Electroporation.’

Other chapters written by a number of different authors address a wide range of topics, including an analysis of tissue electroporation as a bioelectric phenomenon and insight from models into the mechanism of irreversible electroporation in cells.

About AngioDynamics

AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company’s diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.

The views and opinions expressed in the publication "Irreversible Electroporation” are those of the authors alone and do not necessarily represent the views or opinions of AngioDynamics.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu AngioDynamics Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

AngioDynamics Inc. 6,55 0,00% AngioDynamics Inc.

Indizes in diesem Artikel

NASDAQ Comp. 19 060,48 -0,60%